

Atezolizumab (Tecentriq®)

Lungenkarzinom, nicht-kleinzellig (NSCLC) » Nicht-Plattenepithelkarzinom, Kombination 2 » Erstlinie

Empfehlungen der Fachgesellschaft zum Einsatz neuer Arzneimittel

Herausgeber

DGHO Deutsche Gesellschaft für Hämatologie und
Medizinische Onkologie e.V.
Bauhofstr. 12
10117 Berlin

Geschäftsführende Vorsitzende: Prof. Dr. med. Claudia Baldus

Telefon: +49 (0)30 27 87 60 89 - 0

info@dgho.de

www.dgho.de

Ansprechpartner

Prof. Dr. med. Bernhard Wörmann
Medizinischer Leiter

Quelle

www.onkopedia.com

Die Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen entbinden die verantwortliche Ärztin / den verantwortlichen Arzt nicht davon, notwendige Diagnostik, Indikationen, Kontraindikationen und Dosierungen im Einzelfall zu überprüfen! Die DGHO übernimmt für Empfehlungen keine Gewähr.

Inhaltsverzeichnis

1 Atezolizumab, NSCLC, non-squamous, combination 2, first line	... 2
---	--------------

Atezolizumab (Tecentriq®)

Dokument: Fact Sheet

Spezifizierung: Lungenkarzinom, nicht-kleinzellig (NSCLC) » Nicht-Plattenepithelkarzinom, Kombination 2 » Erstlinie

Stand: Juli 2021

1 Atezolizumab, NSCLC, non-squamous, combination 2, first line

Atezolizumab, NSCLC, non-squamous, combination 2, first line

onkopedia				Facts	Appraisal	EU Approval 2019																																																																																																																										
Parameter	Results¹⁴	HR¹⁵	p value	<table border="1" style="width: 100%; text-align: center;"> <tr> <td colspan="9">Evidence (LoE)</td> </tr> <tr> <td>5</td><td>4</td><td>3b</td><td>3a</td><td>2c</td><td>2b</td><td>2a</td><td>1b</td><td>1a</td> </tr> <tr> <td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: black;"></td><td style="background-color: black;"></td> </tr> <tr> <td colspan="9">Clinical benefit (ESMO MCBS)</td> </tr> <tr> <td>1</td><td>2</td><td>3</td><td>4</td><td>5</td> </tr> <tr> <td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: yellow;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td> </tr> <tr> <td colspan="9"> ■ curative ■ non-curative </td> </tr> <tr> <td colspan="4">Patients</td> <td colspan="3" rowspan="6"> <table border="1" style="width: 100%; text-align: center;"> <tr> <td colspan="6">Additional benefit (G-BA)</td> </tr> <tr> <td>lower</td><td>not proven</td><td>not quantifiable</td><td>minor</td><td>considerable</td><td>major</td> </tr> <tr> <td colspan="6">PD-L1 ≥ 50%</td> </tr> <tr> <td style="background-color: black;"></td><td style="background-color: black;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td> </tr> <tr> <td colspan="6">PD-L1 < 50%</td> </tr> <tr> <td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td> </tr> </table> </td> </tr> <tr> <td>Trial</td> <td colspan="3">first line, non-squamous cell carcinoma</td> </tr> <tr> <td>Randomisation</td> <td colspan="3">IMpower130, phase 3</td> </tr> <tr> <td>N¹</td> <td colspan="3">1 : 1 723</td> </tr> <tr> <td>New Therapy</td> <td colspan="3">Carboplatin+nab-Paclitaxel+Atezolizumab</td> </tr> <tr> <td>Control</td> <td colspan="3">Carboplatin+nab-Paclitaxel</td> </tr> <tr> <td>Publication</td> <td colspan="3">DOI:101016/S1470-2045(19)30167-6</td> </tr> </table>			Evidence (LoE)									5	4	3b	3a	2c	2b	2a	1b	1a										Clinical benefit (ESMO MCBS)									1	2	3	4	5						■ curative ■ non-curative									Patients				<table border="1" style="width: 100%; text-align: center;"> <tr> <td colspan="6">Additional benefit (G-BA)</td> </tr> <tr> <td>lower</td><td>not proven</td><td>not quantifiable</td><td>minor</td><td>considerable</td><td>major</td> </tr> <tr> <td colspan="6">PD-L1 ≥ 50%</td> </tr> <tr> <td style="background-color: black;"></td><td style="background-color: black;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td> </tr> <tr> <td colspan="6">PD-L1 < 50%</td> </tr> <tr> <td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td> </tr> </table>			Additional benefit (G-BA)						lower	not proven	not quantifiable	minor	considerable	major	PD-L1 ≥ 50%												PD-L1 < 50%												Trial	first line, non-squamous cell carcinoma			Randomisation	IMpower130, phase 3			N¹	1 : 1 723			New Therapy	Carboplatin+nab-Paclitaxel+Atezolizumab			Control	Carboplatin+nab-Paclitaxel			Publication	DOI:101016/S1470-2045(19)30167-6		
Evidence (LoE)																																																																																																																																
5	4	3b	3a				2c	2b	2a	1b	1a																																																																																																																					
Clinical benefit (ESMO MCBS)																																																																																																																																
1	2	3	4	5																																																																																																																												
■ curative ■ non-curative																																																																																																																																
Patients				<table border="1" style="width: 100%; text-align: center;"> <tr> <td colspan="6">Additional benefit (G-BA)</td> </tr> <tr> <td>lower</td><td>not proven</td><td>not quantifiable</td><td>minor</td><td>considerable</td><td>major</td> </tr> <tr> <td colspan="6">PD-L1 ≥ 50%</td> </tr> <tr> <td style="background-color: black;"></td><td style="background-color: black;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td> </tr> <tr> <td colspan="6">PD-L1 < 50%</td> </tr> <tr> <td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td><td style="background-color: #cccccc;"></td> </tr> </table>			Additional benefit (G-BA)						lower	not proven	not quantifiable	minor	considerable	major	PD-L1 ≥ 50%												PD-L1 < 50%																																																																																																	
Additional benefit (G-BA)																																																																																																																																
lower	not proven	not quantifiable	minor				considerable	major																																																																																																																								
PD-L1 ≥ 50%																																																																																																																																
PD-L1 < 50%																																																																																																																																
Trial	first line, non-squamous cell carcinoma																																																																																																																															
Randomisation	IMpower130, phase 3																																																																																																																															
N¹	1 : 1 723																																																																																																																															
New Therapy	Carboplatin+nab-Paclitaxel+Atezolizumab																																																																																																																															
Control	Carboplatin+nab-Paclitaxel																																																																																																																															
Publication	DOI:101016/S1470-2045(19)30167-6																																																																																																																															

Legende:

¹ N - number of patients

² RR - remission rate, in %

³ PFS - progression-free survival in months

⁵ OS - overall survival in months

⁷ SAE - serious adverse events, CTCAE grade 3/4

¹⁴ results for control, results for new therapy

¹⁵ hazard ratio for new therapy